Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Testimony of John F. Crowley, Executive Chairman…
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
Coalition Letter Supporting Ag Research Funding
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill. 
BIO Comments to FDA on Using Artificial…
In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.
All Letters, Testimony & Comments
  • Show All
Search
September 20, 2023
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
September 11, 2023
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill. 
August 3, 2023
In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.
August 1, 2023
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.
July 28, 2023
In response to a Request for Information (RFI) from the Senate 340B Bipartisan Working Group, BIO submitted detailed comments on the current status of the program and suggestions for improvements.
July 26, 2023
BIO submitted general comments and specific recommendations to the FDA in response to the agency's request for information. (Docket FDA-2022-D-2870)
July 20, 2023
BIO submitted comments on the recent Rare Disease Endpoint Advancement (RDEA) Pilot Program Workshop, held June 7-8, 2023 (Docket No. FDA-2022-N-2480)
July 17, 2023
BIO provides general comments and recommendations on FDA’s Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act (Docket No. FDA-2005-D-0460-0008)
July 17, 2023
BIO provides general comments and recommendations to FDA on “Complying with the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act” (Docket No. FDA-2005-D-0460-0007)